HMHideki Matsumoto

Hideki Matsumoto

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hideki Matsumoto has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Hironobu Endo

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

    3 shared publications
  • Kazunori Kawamura

    Department of Advanced Nuclear Medicine Sciences, Institute for Quantum Medical Science National Institutes for Quantum Science and Technology (QST) Chiba Japan

    3 shared publications
  • Keisuke Takahata

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

    3 shared publications
  • Kenji Tagai

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

    3 shared publications
  • Yuki Momota

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

    3 shared publications
  • Asaka Oyama

    Advanced Neuroimaging Center, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology (QST), Chiba, Japan

    2 shared publications

Latest Publications

  • In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy

    by Yuko Kataoka, Ryoji Goto, Yoshikazu Chishiki, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Sho Moriguchi, Yuki Momota, Tetsuji Kamada, et al.

  • Open Access

    Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET

    by Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, et al.

    Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (ΔSUVR) in PSP relative to HCs, alongside regions where ΔSUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.

  • Distinct tau pathologies in the nucleus basalis of Meynert between early-onset and late-onset Alzheimer's disease patients revealed by positron emission tomography

    by Hisaomi Suzuki, Kenji Tagai, Maiko Ono, Hiroshi Shimizu, Hironobu Endo, Hideki Matsumoto, Manabu Kubota, Yuko Kataoka, Sho Moriguchi, Shin Kurose, et al.

    Background: Tau accumulation in the nucleus basalis of Meynert (nbM) has been documented in Alzheimer's disease (AD), but its relationship to neuropathological changes in other brain regions and cognitive deficits remains unclear, particularly between early-onset AD (EOAD) and late-onset AD (LOAD). Objective: To evaluate tau accumulation patterns in the nbM and other brain regions in EOAD and LOAD using 18 F-florzolotau PET and examine correlations with cognitive function. Methods: Thirty-eight amyloid-positive AD patients (15 EOAD, 23 LOAD) and 46 healthy controls underwent 18 F-florzolotau PET. Tau levels were quantified in the nbM and Braak-staging regions. Postmortem brain samples were examined to assess 18 F-florzolotau binding to tau deposits. Results: EOAD showed a higher overall tau burden, including in the nbM, compared with LOAD. However, nbM tau levels correlated more strongly with cognitive decline in LOAD than EOAD. The relationship between nbM tau and neocortical tau differed between EOAD and LOAD. Histopathology revealed abundant 18 F-florzolotau labeling of neurofibrillary tangles (NFTs) and ghost tangles in AD nbM samples. Conclusions: This study provides the first in vivo PET evidence of differential nbM tau pathology between EOAD and LOAD, with higher accumulation but weaker correlation to cognition in EOAD. The distinct relationships between nbM and cortical tau in EOAD and LOAD suggest divergent pathological trajectories. 18 F-florzolotau PET successfully visualized NFTs and extracellular ghost tangles in the nbM across AD stages. These findings highlight the importance of considering age of onset when evaluating tau pathology and its clinical correlates in AD.